Sponsors (4)
The bill promotes U.S.–Israel collaboration to speed medical R&D, strengthen health-system capacity, and create workforce and infrastructure benefits, while posing trade-offs around patient data privacy, potential industry concentration, regulatory/IP impacts on competition and cost, cybersecurity, and ongoing taxpayer expense.
Patients (including those with chronic conditions) could get access to improved treatments sooner through coordinated clinical trials, regulatory collaboration, and Project Orbis participation.
U.S. and Israeli health systems can strengthen clinical capacity and share best practices, improving pandemic and disease response capabilities.
Workforce training and exchange programs will build manufacturing and technical skills, supporting domestic biological product production and related jobs.
Sharing health data with a foreign government raises privacy and data‑protection risks for U.S. patients if safeguards are not strong and enforceable.
Regulatory harmonization and stronger IP protections could favor industry commercialization, limit competition, and potentially raise costs for patients and smaller firms.
Cross‑border expansion of digital health and telemedicine increases cybersecurity and operational risks if interoperability and privacy standards are not rigorously enforced.
Based on analysis of 2 sections of legislative text.
Authorizes HHS to run a U.S.–Israel program to coordinate joint medical R&D, regulatory alignment, manufacturing, telehealth, and disease prevention, with up to $8M/year (FY2026–2030).
Introduced January 23, 2025 by Vernon G. Buchanan · Last progress January 23, 2025
Creates a U.S. program, run by HHS in coordination with Commerce, CMS, and FDA, to promote joint U.S.–Israel work on medical research, product development, regulatory alignment, manufacturing, telemedicine, disease prevention, and health system strengthening. The program may include a U.S.-based joint collaboration center and must begin implementation within six months of enactment. Authorizes up to $8 million per year for fiscal years 2026–2030 (subject to appropriations) to support coordination, R&D partnerships, regulatory cooperation, workforce training, supply-chain resilience, and public–private projects related to biologics, digital health, vaccines, and related technologies.